CD8A and glioblastoma: These induced cells act synergistically with PD-decoy immunotherapy and a CD-based glioblastoma vaccine with robust killing of highly resistant glioblastoma cells by tumor-specific CD8+ CTLs with significant improval in survival in immunocompetent animals (150).